Singapore markets closed

ABBV Jan 2024 145.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
13.57-3.63 (-21.10%)
As of 12:49PM EDT. Market open.
Full screen
Loading interactive chart…
  • Motley Fool

    Here's Why This Dividend King Is a Buy

    Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.

  • Motley Fool

    Where Will AbbVie Be in 3 Years?

    In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.

  • Motley Fool

    Where to Invest $10,000 Right Now

    Prolonged periods of volatility along with dips near or even into bear market territory have become commonplace for investors in recent months as fears of a looming recession, geopolitical headwinds, and ongoing concerns about the global economy continue to remain front of mind. For investors who have the capital to put to work right now, even a market like the one we're seeing presents its own share of opportunities to invest in these types of compelling companies at a bargain. Healthcare stocks had quite the heyday in the early pandemic, when investors were rushing to put their cash into any and all companies in this space.